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ABSTRACT 
Metastasis is a multistep process that is critically dependent on the interaction of metastasizing 
tumor cells with cells in the local microenvironment. Within this tumor stroma, vessel-associated 
pericytes and myofibroblasts share a number of traits including the upregulated expression of the 
transmembrane receptor endosialin (CD248). Comparative experiments in wildtype and endosialin-
deficient mice revealed that stromal endosialin does not affect primary tumor growth but strongly 
promotes spontaneous metastasis. Mechanistically, endosialin-expressing pericytes in the primary 
tumor facilitate distant site metastasis by promoting tumor cell intravasation in a cell contact-
dependent manner resulting in elevated numbers of circulating tumor cells. Corresponding to these 
preclinical experiments, in independent cohorts of primary human breast cancers, upregulated 
endosialin expression significantly correlates with increased metastasis and poorer patient survival. 
Together, the data demonstrate a critical role for endosialin-expressing primary tumor pericytes in 
mediating metastatic dissemination and identify endosialin as a promising therapeutic target in 
breast cancer. 
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INTRODUCTION 
The vast majority of cancer-related mortality is due to distant site metastasis and not to primary 
tumor growth. Metastasis thereby marks the transition from a local to a systemic disease. The 
multistep nature of metastatic tumor cell dissemination and colonization is widely appreciated (1). 
Yet, the molecular and mechanistic understanding of individual steps of the metastatic cascade and 
the identification of bottlenecks that could serve as therapeutic targets is still in its infancy.  
 Metastatic progression is critically dependent on the interaction of metastasizing tumor cells 
with the cells of their microenvironment, both at the primary tumor site as well as at the site of 
metastasis (2,3). Among the cells of the tumor microenvironment, stromal myofibroblasts, 
macrophages and other inflammatory cells, as well as cellular constituents of blood and lymphatic 
vessels, i.e. endothelial cells, pericytes and vascular smooth muscle cells, comprise the tumor stroma 
(4,5). Interestingly, tumor-associated pericytes and stromal myofibroblasts share a number of 
functional and molecular traits including the expression of the cell surface receptor endosialin 
(CD248).  
 Endosialin (CD248) is a transmembrane glycoprotein (6) that was originally described as a 
cell surface marker of the tumor endothelium (7,8). However, high-resolution morphological analyses 
of a range of human cancers have unequivocally demonstrated that endosialin is not expressed by 
endothelial cells, but by pericytes and myofibroblasts (9-13). Importantly, resting mesenchymal cells 
in the healthy adult have low or undetectable levels of endosialin expression. Expression is 
essentially restricted to activated cells of the mesenchymal lineage during embryogenesis (10,14) as 
well as during pathological states including tumor progression and metastasis (13,15,16), making 
endosialin an oncofetal protein with potential as a biomarker and a therapeutic target (17-20). In 
fact, clinical trials in solid tumors and lymphomas with an endosialin targeting antibody are ongoing 
(www.clinicaltrials.gov/ct2/results?term=endosialin&Search=Search) (21). 
 Functionally, endosialin regulates mesenchymal cell proliferation through PDGFRβ signaling 
(22,23), which has been associated with the promigratory mesenchymal cell phenotype (24-26). 
Endosialin-deficient mice are, unless pathologically challenged, phenotypically normal (27), although 
4 
 
they display some delay of developmental vascular remodeling caused by perturbed pericyte 
function (28, 29). Earlier studies have reported no overt difference in the growth of subcutaneous 
tumors in wildtype and endosialin-deficient mice (27,28,30). Yet, transplantable colorectal tumors 
grown orthotopically in endosialin-deficient mice,  displayed a prominent reduction in primary tumor 
growth, invasion and metastasis compared to endosialin wildtype tumor-bearing mice (27). This 
striking difference between subcutaneous and orthotopic tumor growth in endosialin-deficient mice 
prototypically highlights the important contribution of the microenvironment to tumor progression 
and metastasis and identifies endosialin as a functionally relevant receptor in the tumor stroma. At 
the same time, pericytes have been shown to limit metastasis in the Rip1Tag2 model of pancreatic β 
cell tumorigenesis (31). Conceptually linking these two totally independent lines of research, we 
hypothesized that the upregulated expression of endosialin by tumor-associated pericytes may be an 
important contributor to tumor progression and metastasis. We consequently set out to 
systematically dissect the role of endosialin in the control of individual steps of the metastatic 
cascade. These experiments yielded unexpected mechanistic insights into the role of endosialin in 
regulating metastasis and identified the control of tumor cell intravasation by activated pericytes as a 
critical and rate-limiting step.   
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METHODS 
In vivo studies 
In vivo experiments were carried out under a UK Home Office Project license 70/7413 or under 
ethical guidelines of the local Animal Use and Care Committees approved by the 
Regierungspräsidium in Karlsruhe, Germany [35-9185.81/G-195/10]. Animals were housed in barriers 
at the animal facility of the DKFZ or in Optimice cages at the ICR. All animals were monitored on a 
daily basis for signs of ill health and had free admission to food and water. 129/Sv mice with a global 
knockout of endosialin were kindly provided by Dr. David Huso (Johns Hopkins Medical Institutions, 
Baltimore, USA) (27). Mice were backcrossed for 6 generations with either BALB/c (Charles River), 
Swiss nude mice (Charles River) or C57BL/6 (DKFZ) mice. Genotypes were confirmed by PCR. 
 For spontaneous metastasis assays, 4T1 tumor cells were injected into the mammary fat pad 
or subcutaneously in 6-10 weeks old female WT or ENKO BALB/c or Swiss nude mice. LLC cells were 
implanted subcutaneously in the flank of 8-10 weeks old WT or ENKO C57BL/6 mice. Tumor size was 
monitored by IVIS imaging. Tumor volume was calculated as 0.5 x length x width2.  
 For 4T1 or LLC tumor resection, primary tumors were removed under general anesthesia. 
Mice with tumors not effectively removed or with subsequent tumor recurrence were removed from 
analyses. Mice were sacrificed at the indicated time points or when they showed signs of ill health. 
 Protocols for tissue processing, vascular leakage and hypoxia assessment are described in the 
Supplementary Data. 
 
Ex vivo culture of circulating tumor cells 
Arterial blood was isolated by cardiac puncture and 100µL plated in DMEM plus 10% FCS per 10cm 
tissue culture plate. Tumor cell colonies were stained 14 days later with crystal violet. Plates were 
scanned at 300dpi on EpsonV700 scanner and analyzed by Adobe Photoshop CS6.  
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Cells 
4T1 cells (ATCC, 2013), 4T1 cells expressing luciferase (4T1-Luc; provided by Dr. K. Srivastava, DKFZ, 
2014), 4T1 or 4T1-Luc cells expressing RFP (4T1-RFP, 4T1-Luc-RFP) were cultured in DMEM or RPMI 
(Invitrogen) plus 10% FCS (Invitrogen). Lewis lung carcinoma cells (LLC; obtained from ATCC, 2006) 
were cultured in DMEM supplemented with 10% FCS, 1% penicillin/streptomycin. Human MDA-MB-
231-LM2 expressing luciferase and GFP (MDA-MB213-Luc-GFP; provided by Dr. C. Lowry, DKFZ, 2014) 
cells were cultured in DMEM plus 10% FCS, 1% penicillin/streptomycin. Cell authentication by 
Multiplexion GmbH resulted in 98% identity towards MDA-MB-231 cells (Dec. 2015).  
 Human umbilical vein endothelial cells (HUVEC, Nov. 2015, tested by Promocell via flow 
cytometry and PCR) were cultured in Endopan3 medium with supplements (PAN, Biotech GmbH). 
The immortalized mouse endothelial cell line sEND (provided by R. Bicknell, University of 
Birmingham) was cultured in DMEM plus 10% fetal calf serum. Human brain vascular pericytes (BP, 
Nov. 2015, tested by ScienCell via immunofluorescence and PCR) and 10T1/2 cells (ATCC, 1997) were 
cultured in pericyte medium (ScienCell) plus 2% FCS, 1% of the corresponding pericyte growth 
supplement (PGS) and 1% penicillin/streptomycin, according to manufacturer´s protocol. BP were 
infected with pGIPZ lentiviral vectors (Dharmacon) containing control (shNT, GIPZ shRNA Empty 
Vector; RHS4349) or endosialin-targeting (shEN: V2LHS_34217) shRNAs at a multiplicity of infection 
(MOI) of 10. 10T1/2 cells were infected with MISSION shRNA lentivirus particles (Sigma) encoding 
non-targeting (SHC002V) endosialin targeting (shEN; TRC0000098115) shRNAs at a MOI of 5. Cells 
were selected in puromycin. Primary mouse brain pericytes were isolated as previously described 
(32). All cell lines were routinely tested for mycoplasma by PCR and tested negative. 
 
Transwell migration assay  
10T1/2 cells (7.5x105) or mouse brain pericytes (7.5x105) on their own or with sEND endothelial cells 
(5x105) plated on the abluminal side of the filter, were plated in pericyte medium onto the upper 
chamber of 24mm 8.0µm pore Matrigel-coated Transwell filters (Corning) for 24 hours. 24 hours 
later, 4T1-RFP cells (5x105) were added to the upper chamber in 2% FCS supplemented AdvDMEM, 
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with 20% FCS supplemented AdvDMEM in the bottom chamber. 24 hours later, Transwells were 
washed, transmigrated cells detached in trypsin/EDTA and 4T1-RFP cell number quantified on LSRII 
FACS analyzer. 
 HUVEC (1x105) were seeded onto the upper chamber of 6.5 mm/8.0 µm 0.2% gelatin-coated 
Transwells (Corning) overnight. Human brain pericytes (BP) (2x104) were added to the upper 
chamber. 5 hours later, MDA-MB-231-LM2 cells (1x104, stained with PKH67 red fluorescent dye 
(Sigma)) were added to the upper chamber in 2% FCS supplemented GlutaMAX with 10% FCS 
supplemented GlutaMAX in the bottom chamber. 6 hours later, Transwells were washed, fixed with 
Roti-Histofix 4% for 10 minutes and cell number analyzed by fluorescent microscopy (10x 
magnification, 6 fields per filter) and quantified by ImageJ. Where indicated, BP were replaced with 
BP conditioned medium.  
 
Cell adhesion assay 
shNT or shEN 10T1/2 cells (1.5x105) or isolated mouse brain pericytes (1.5x105) were seeded in 24-
well plates and were allowed to form a confluent monolayer. 4T1-RFP cells (7.5x104) were seeded on 
top and allowed to adhere for 15 or 30 minutes. Non-adhered 4T1-RFP cells were removed by 
washing, remaining cells were detached and analyzed by FACS.  
 
Patient samples   
The German study was registered at the tissue bank of the National Center for Tumor Diseases (NCT, 
Heidelberg, Germany) and performed according to the declaration of Helsinki; written informed 
consent was obtained from all patients. All patient specimen and corresponding clinical information 
were exclusively provided in a pseudonymized form according to the Standard Operating Procedures 
of the NCT, approved by the ethic committee of the University of Heidelberg (Ethics Votes #206/207, 
year 2005). The UK sample collection was approved by the research ethics committee of the Royal 
Marsden NHS Foundation Trust.  
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Statistical analysis 
Statistics were performed using GraphPad Prism 6. Unless otherwise stated, all numerical data are 
expressed mean±standard error of the mean (SEM). All comparisons between 2 groups were made 
using the two-tailed, unpaired Student’s t-test, if not indicated otherwise. Unless otherwise stated in 
the figure legend, *=P<0.05, **=P<0.01 and ***=P<0.001.  
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RESULTS 
Stromal expression of endosialin does not affect primary tumor growth but promotes spontaneous 
metastasis  
To investigate the role of stromal endosialin on tumor metastasis, we compared growth and 
metastatic progression of orthotopic syngeneic 4T1 mammary tumors in BALB/c wildtype (WT) and 
endosialin-deficient (ENKO) mice. Confocal microscopy and gene expression profiling of 4T1 tumors 
revealed that endosialin expression on the tumor vasculature was restricted to pericytes with no 
detectable expression on endothelial cells (Supplementary Fig. S1). No significant differences in 
primary tumor growth were detected (Fig. 1A), nor in primary tumor weight at necroscopy 
(Supplementary Fig. S2A). In contrast, there was a significant reduction in spontaneous metastasis in 
ENKO compared to WT mice, as monitored by tumor burden in the lungs (Fig. 1B and C). Metastatic 
progression was limited in these experiments by the growth of the primary tumor. To circumvent this 
limitation and better mimic the clinical setting, 4T1 primary tumors were surgically resected at small 
size (day 9; ~100mm3) and metastatic progression was traced until mice were culled for ethical 
reasons or the experiment terminated. Consistent with the data in Fig. 1A, there was no significant 
difference in the weight of the primary tumors at resection (Supplementary Fig. S2B). However, only 
30.7% of WT mice, compared to 70.0% of ENKO mice, survived to termination of the experiment (day 
93, Fig. 1D). Examination of lung metastatic burden revealed a significantly reduced number of 
pulmonary tumor nodules in ENKO compared to WT mice (Fig. 1E). Of note, surviving mice at the end 
of the experiment had no detectable metastatic disease in the lungs.  
 To exclude possible adaptive immunity related effects in the observed metastasis phenotype, 
we next performed 4T1 metastasis experiments in Swiss nude WT and ENKO immunocompromised 
mice. Again, there was no significant difference in primary tumor growth (Fig. 1F and G; 
Supplementary Fig. S2C). However, metastatic burden as monitored by ex vivo IVIS imaging was 
significantly reduced in ENKO mice (Fig. 1H). Moreover, IVIS imaging of individual organs revealed a 
significant reduction in metastasis not just to the lungs, but also to liver, lymph nodes, spleen, brain 
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and bone (Fig. 1H and I; Supplementary Fig. S2D-I), indicating that the decrease in metastasis in 
BALB/c ENKO mice was not dependent on an intact immune system. 
 To validate the 4T1 metastasis phenotype in a second tumor model, Lewis lung carcinoma 
(LLC) cells were grown subcutaneously in C57BL/6 WT and ENKO mice and tumors were surgically 
resected at day 16 (~300mm3). As with the 4T1 tumors, endosialin expression in the LLC tumor 
vasculature was restricted to pericytes (Supplementary Fig. S1C). There was no significant difference 
in primary tumor growth (Fig. 2A), but there was a significant reduction in the number of ENKO mice 
with histologically detectable metastases in the lungs upon termination of the experiment (day 35; 
Fig. 2B and C).  
 
Endosialin does not affect metastatic seeding or colonization 
Based on the prominent metastasis phenotype in the absence of an overt primary tumor phenotype, 
we hypothesized that stromal endosialin might affect metastatic seeding and/or colonization. 
Consequently, we studied metastatic colonization upon tail vein injection of 4T1 (Fig. 3A-D) or LLC 
(Fig. 3E and F) cells in WT and ENKO mice. There was no difference in lung tumor burden between 
experimental groups in either tumor model, indicating that stromal endosialin plays no role in 
metastatic seeding or colonization. 
 
Primary tumors in ENKO mice show no defects in stromal architecture 
The exclusion of an effect of endosialin on metastatic seeding and colonization prompted us to 
analyze in greater detail stromal attributes of primary tumors grown in WT and ENKO mice. In 
particular, given the well documented upregulation of endosialin expression on pericytes in the 
tumor vasculature (9-13), we examined the architecture and functionality of tumor vessels. 4T1 
primary tumors grown in BALB/c (Fig. 4A and B; Supplementary Fig. S3A and B) and 
immunocompromised mice (Fig. 4D and E) or LLC primary tumors (Supplementary Fig. S3C and D) 
revealed no significant differences in the number of tumor microvessels, total vessel area, vessel 
caliber distribution or deposition of collagen IV in the vascular basement membrane between WT 
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and ENKO mice. Likewise, vessel maturation, as assessed by pericyte coverage through αSMA and 
desmin staining, did not differ in tumors grown in WT or ENKO mice (Fig. 4C and F; Supplementary Fig. 
S3E and F). Similarly, functional experiments showed no difference in vessel perfusion (data not 
shown) or permeability as monitored by leakage of Hoechst dye (Fig. 4G and H) or Evans blue 
(Supplementary Fig. S4A and B). Consistent with the indistinguishable structural and functional vessel 
attributes, primary tumor hypoxia, necrosis, tumor cell proliferation or apoptosis did not differ 
between WT and ENKO mice in either tumor model (Fig. 4I-L, Supplementary Fig. S4C-G). Finally, given 
that endosialin is also expressed by myofibroblasts, we assessed stromal collagen deposition in the 
primary tumors by Sirious red staining and the distribution and abundance of αSMA-positive 
myofibroblasts, which again showed no differences between the experimental groups 
(Supplementary Fig. S4H-J). Taken together, these studies revealed no discernible structural stromal 
differences between tumors in WT and ENKO mice that could account for the prominent metastatic 
phenotype of endosialin-deficient mice.  
 
Stromal endosialin promotes tumor cell intravasation 
A key role of pericytes is in stabilizing the normal vasculature (33). Given the striking upregulation of 
endosialin expression on tumor-associated pericytes (9-13), we next addressed whether tumor cells 
displayed an altered propensity to intravasate into the vasculature in WT and ENKO mice. Consistent 
with the data in Figure 1, 4T1 primary tumor growth was indistinguishable between the experimental 
groups, but ENKO mice showed a significant reduction of spontaneous lung metastasis as monitored 
by digital droplet PCR (Fig. 5A and B). Importantly, tumor cell colonies derived from arterial blood 
were significantly reduced in ENKO mice (Fig. 5C and D), indicating that stromal endosialin regulates 
intravasation of tumor cells from the primary tumor into the circulation.  
 To test this hypothesis directly, we performed in vitro tumor cell transmigration assays across 
a pericytes monolayer (Supplementary Fig. S5A and B). 10T1/2 pericyte-like cells expressing non-
targeting (shNT) or endosialin-targeting (shEN) shRNAs (Fig. 6A; Supplementary Fig. S6A) were 
cultured on Matrigel-coated Transwell filters for 24 hours prior to addition of 4T1-RFP tumor cells. 
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Transmigrated cells were quantified 24 hours later by FACS analysis. The presence of endosialin-
expressing shNT 10T1/2 cells, but not shEN 10T1/2 cells with downregulated endosialin expression, 
enhanced transmigration of 4T1-RFP cells (Fig. 6B). To ensure that these effects were not restricted 
to 10T1/2 cells, the experiment was repeated using pericytes isolated from the brains of non-tumor 
bearing WT and ENKO mice (Fig. 6C and D; Supplementary Fig. S6B). Again, the presence of WT 
pericytes, but not ENKO pericytes, enhanced the transmigration of co-cultured 4T1-RFP cells (Fig. 6D). 
To validate the tumor cell transmigration enhancing effect of pericyte-expressed endosialin, we 
examined the ability of human MDA-MB-231 breast cancer cells to transmigrate across a layer of 
shNT or shEN human brain pericytes (Supplementary Fig. S6C-E). As with the mouse cell experiments, 
the presence of shNT-human pericytes, but not shEN-pericytes, promoted transmigration of the co-
cultured human tumor cells (Fig. 6E). 
 Finally, to closer model tumor cell intravasation, we mimicked the 3D assembly of the normal 
vessel wall by allowing tumor cells to transmigrate across sandwich-cultured HUVEC or microvascular 
endothelial cells and pericytes (Supplementary Fig. S5C and D). As in tumors (see Supplementary Fig. 
S1) neither HUVEC (9) nor microvascular endothelial cells (Supplementary Fig. S7A) express 
endosialin. The presence of endosialin-expressing pericytes significantly promoted tumor cell 
transmigration across the endothelial cell monolayer (Fig. 6F). Equivalent results were obtained using 
mouse microvascular endothelial cells and shEN or shNT 10T1/2 cells (Supplementary Fig. S7B). 
Notably, there was no difference between tumor cell transmigration across the endothelial 
monolayer in the presence of pericytes with downregulated endosialin expression and across an 
endothelial cell monolayer without pericytes, indicating that endosialin-expressing pericytes actively 
promote tumor cell intravasation into the vasculature.   
 
Stromal cell endosialin effects on tumor cell intravasation are cell contact-dependent  
To shed further insights into the mechanism by which stromal endosialin promotes tumor cell 
intravasation, we performed transmigration experiments in the presence of pericyte-conditioned 
medium (Supplementary Fig. S5E). The promotion of tumor cell transmigration by endosialin-
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expressing pericytes could not be recapitulated by replacing pericytes with pericyte-conditioned 
medium (Fig. 6G) indicating that enhanced tumor cell migration was not solely dependent on 
promigratory factors secreted by endosialin-positive pericytes. Consequently, we set out to 
determine, if endosialin mediated direct cell-cell interactions between pericytes and tumor cells. To 
this end, we performed adhesion assays with both shNT and shEN 10T1/2 pericyte-like cells and brain 
pericytes isolated from WT and ENKO mice. With both cells types, adhesion of 4T1-RFP cells was 
significantly impaired by downregulation or genetic deletion of endosialin (Fig. 6H and I).  
 Finally, we investigated whether a pericyte remodeled matrix could substitute for the 
promigratory cell-cell contact dependent phenotype observed with intact pericytes. 10T1/2 cells and 
isolated brain pericytes were allowed to remodel the matrix of Matrigel-coated Transwell filters, 
prior to decellularization by ammonium hydroxide treatment (Supplementary Fig. S5F). Notably, the 
enhanced transmigratory phenotype of 4T1-RFP cells co-cultured with live shNT pericytes was not 
recapitulated by a pericyte-remodeled matrix (Supplementary Fig. S7C). Similarly, the increased 
adhesion of 4T1 cells to WT pericytes was not recapitulated in an adhesion assay where WT pericytes 
were replaced by WT pericyte-derived extracellular matrix (Supplementary Fig. S7D).  These data 
indicate that the presence of live endosialin-expressing pericytes is required to induce the 
promigratory, cell-cell contact dependent intravasation phenotype of tumor cells. 
 
Endosialin expression on primary human carcinoma samples primes for metastatic spread 
Based on the prominent role of stromal endosialin in mediating metastasis in preclinical mouse 
models, we assessed the clinical relevance of these experimental findings. First, comparison of 
microdissected breast tumor stroma and normal adjacent stroma displayed a significantly higher 
level of endosialin (CD248) mRNA in the tumor stroma (Fig. 7A). Next, we stained human primary 
invasive breast cancer samples with two independent anti-endosialin monoclonal antibodies (B1/35 
and FB5) (9). As illustrated in Figure 7B, variable expression of endosialin was detected on tumor 
pericytes and stromal myofibroblasts. However, with the exception of a rare subset of metaplastic 
breast cancers, no endosialin expression was detected on tumor cells. When comparing endosialin 
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protein and CD248 mRNA levels in the primary tumor with the metastatic stage, a significant 
correlation was observed between endosialin protein (Fig. 7C; Supplementary Fig. S8A) and mRNA 
levels (Fig. 7D) with increased incidence of metastasis. In particular, higher CD248 expression in the 
primary tumor was found in patients with distant metastasis to the lung, liver and bone as compared 
to patients without detectable metastatic disease (Supplementary Fig. S8B). Importantly, 
examination of CD248 expression in microdissected breast tumor stroma (34) revealed a significant 
association between high stromal CD248 expression and decreased recurrence-free survival (Fig. 7E), 
whereas high CD248 expression in a dataset of 334 lymph-node positive breast cancers (35) was 
significantly associated with decreased distant metastasis-free survival (Fig. 7F). Taken together, 
these data indicate that endosialin expression in the primary tumor serves as poor prognostic factor 
for the development of metastatic disease. 
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DISCUSSION 
Endosialin (CD248) is a mesenchymal cell surface receptor that is widely expressed during embryonic 
development and downregulated in healthy adult tissues (10,11,14,25). Endosialin may be 
abundantly expressed in the adult upon pathological challenge, most notably by pericytes and 
myofibroblasts in the tumor-associated stroma (7,9,11,12,14) as well as in fibrotic (26) and 
atherosclerotic tissues (HGA, unpublished data). Although endosialin was originally named TEM1 
(tumor endothelial marker 1) (6,8), this was later shown to be a misleading nomenclature when 
different laboratories reported endosialin expression being restricted to stromal pericytes and 
myofibroblasts and absent from endothelial cells of various human and mouse tumors 
(9,11,12,25,36). The downregulated expression in the adult in combination with the striking 
upregulation in tumors makes endosialin an oncofetal protein that is in principle, strictly based on its 
unique pathology-associated expression pattern, an attractive therapeutic target. Indeed, we 
demonstrate here, in three different pre-clinical models that stromal endosialin expression facilitates 
spontaneous distant site metastasis. To mechanistically unravel the role of stromal endosialin during 
individual steps of tumor progression and metastasis, we set out comparative tumor experiments in 
wildtype (WT) and endosialin-deficient (ENKO) mouse models and in 3D in vitro reconstitution assays. 
Complementing these studies with the analysis of human breast cancer expression datasets, we 
show that (i) enhanced spontaneous metastasis in WT mice requires upregulated endosialin 
expression on tumor-associated pericytes to promote tumor cell intravasation into the circulation, (ii) 
endosialin mediates direct cell-cell interactions of tumor-associated pericytes and tumor cells to 
promote tumor cells transmigration across an endothelial monolayer, and (iii) breast cancer patients 
with high primary tumor endosialin expression have significantly higher rates of metastasis and 
reduced recurrence-free survival. 
 Previous studies addressing the role of pericytes in tumorigenesis have focused on ablating 
pericytes (37,38) or blockade of PDGFRβ signaling in pericytes by genetic targeting (31), 
pharmacological inhibition (39), PDGFRβ blocking antibodies (37,40) or PDGF-B binding 
oligonucleotide aptamers (41). All these strategies resulted in loss of pericyte coverage on the tumor 
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vasculature, subsequent vascular destabilization and, in most cases, a reduction in tumor volume. 
Intriguingly, where it was examined, this vascular destabilization and inhibition of tumor growth, 
potentially enhancing tumor hypoxia and inducing tumor cell EMT, was accompanied by increased 
metastatic spread (31,37,38). Indeed, low pericyte coverage in clinical samples is associated with 
poor patient prognosis (42,43). These findings are reminiscent of recent studies demonstrating that 
two independent genetic strategies to reduce myofibroblasts in the stroma of pancreatic cancers 
resulted in enhanced tumor aggressiveness (44,45). However, while genetic deletion of Shh resulted 
in enhanced tumor growth (45), pharmacological targeting of the Hh pathway improved drug 
delivery and reduced tumor invasion and metastasis (46,47). These contrasting data reinforce the 
notion that stromal effects on tumor progression and metastasis may be highly contextual and that 
stromal cells can play both tumor promoting and tumor suppressing roles dependent on the tumor 
type and location. This has led to the concept that it may be more effective to deploy strategies to 
"normalize" or de-differentiate tumor-associated stromal cells rather than target them for 
destruction. 
Consistent with this concept, unlike targeting PDGFRβ or ablating pericytes, treatment of 
syngeneic tumor bearing human CD248 knock-in mice with the anti-human endosialin antibody 
MORAb-004 did not result in a reduction in vessel number or destabilization of the vasculature, as 
monitored by endothelial cell viability, pericyte coverage and integrity of the basement membrane, 
but significantly impaired the growth of B16-F10 tumors following subcutaneous or intravenous 
inoculation (36). Importantly, in the study reported here, the impairment in metastatic dissemination 
in the ENKO mice was not associated with gross alterations in the tumor vasculature. Primary tumors 
in both syngeneic and immunocompromised WT and ENKO mice were indistinguishable in terms of 
vessel architecture including, as previously observed in the developing retinal vasculature of ENKO 
mice (28), no detectable loss in pericyte coverage. Similarly, there were no significant differences in 
vascular patency in WT and ENKO tumors as monitored by vessel perfusion, vascular leakage and 
levels of primary tumor hypoxia and necrosis, indicating that an inability to upregulate endosialin 
expression in the tumor stroma has minimal impact on vascular integrity. Importantly, in primary 
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tumors from ENKO mice, the number or distribution of αSMA-expressing myofibroblasts was not 
altered suggesting that the expression of endosialin by myofibroblasts is not the driving force of 
tumor cell dissemination and intravasation. Consistent with this lack of stromal disruption, no 
differences in primary tumor growth in WT and ENKO mice were detected in the three tumor models 
used in this study. Previous studies also reported no differences in LLC or B16-F0 subcutaneous 
primary tumor growth in WT and ENKO mice (27,28) or following intracranial inoculation of C57MG 
glioblastoma cells (30). In contrast, when HCT116 colorectal tumor fragments were orthotopically 
grafted onto the intestinal surface, tumors in the ENKO mice were reduced in volume and showed 
reduced local invasion and metastasis (27). The mechanism underlying these effects was not 
investigated, but the data demonstrate that stromal endosialin modulation of primary tumor growth 
may vary depending on the tumor site and the conditions of the microenvironment.  
To relate endosialin to distinct steps of the metastatic cascade, we performed seeding and 
colonization experiments by intravenous injection of tumor cells. These experiments revealed 
unambiguously that endosialin was not involved in secondary site colonization. We therefore focused 
on the intravasation of cells from the primary tumor as a possible rate-limiting step of metastasis. 
Indeed, while microvessel permeability were indistinguishable in primary tumors grown in WT and 
ENKO mice, the expression of endosialin had a pronounced effect on the ability of tumor cells to enter 
the systemic blood circulation. Of note, we observed in comparative studies a reduction in 
spontaneous metastasis in both ENKO immunocompetent and immunocompromised mice, which 
ruled out an involvement of an intact immune system as an effector of the endosialin-mediated 
metastasis phenotype. Recently, the presence of macrophages at tumor cell intravasation sites has 
been shown to promote tumor cell intravasation (48,49), however, analysis of tumors growing in WT 
or ENKO mice did not yield any significant differences in macrophage numbers indicating that 
macrophages are not the driving force for endosialin-mediated tumor cell intravasation (C.K. & 
H.G.A., unpublished data). In conclusion, although the mechanisms of tumor cell intravasation are 
not well elucidated, these data indicate that the interaction of tumor cells with both pericytes and 
endothelial cells may play a role (50). 
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To delineate more directly the roles of individual cell populations, we mimicked the 
multicellular vascular crosstalk in a modified Transwell migration assay. Pericytes with or without 
endosialin expression were co-cultured with endothelial cells, and tumor cells were analyzed for their 
ability to transmigrate across the endothelial layer. These in vitro reconstruction experiments 
validated the in vivo findings to show that endosialin expression by pericytes alone stimulated tumor 
cell transmigration. Importantly, this stimulatory behavior of endosialin-positive pericytes was 
independent of the effect of pericytes on endothelial cells as enhanced tumor cell transmigration 
was still observed in the absence of an endothelial monolayer. Moreover, this ability of endosialin-
positive pericytes to promote tumor cell transmigration could not be recapitulated by pericyte 
conditioned medium or pericyte remodeled extracellular matrix indicating a requirement for a direct 
interaction between tumor cells and tumor pericytes during intravasation. While the detailed 
molecular mechanisms mediating this interaction await elucidation, analysis of global gene 
expression data of primary tumor cells isolated from WT and ENKO tumor-bearing mice indicate that 
endosialin-positive stroma does not alter the intrinsic tumor cell transcriptional profile (C.V. & C.M.I., 
unpublished data), rather that it functions to modulate the local microenvironment. Indeed, it has 
been reported previously that recombinant endosialin can bind in in vitro assays to extracellular 
matrix components, including collagen and fibronectin (24), and in vivo to the vascular basement 
membrane (28). Thus, based on the available data, we hypothesize that endosialin does not function 
as an active metastasis promoting signaling factor in educating tumor cells to gain invasive behavior, 
but rather as a facilitator tethering tumor cells to the matrix and actively mediating their 
transmigration through the vascular basement membrane and underlying endothelial monolayer.  
In conclusion, the data presented here causally link the expression of a metastasis-facilitating 
stromal receptor to a very specific step of the metastatic cascade and shed important mechanistic 
insight into the role of tumor-associated pericytes in mediating tumor metastasis. Importantly, the 
clinical relevance of these preclinical tumor experiments, involving independent tumor models with 
corresponding mechanistic cellular experiments could be validated by comparative pathology of 
human tumors. Indeed, analysis of human breast cancer samples revealed that the abundance of 
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primary tumor stromal endosialin expression strongly correlated with metastatic progression and 
reduced recurrence-free survival. Consequently, the findings of this study and the unique oncofetal 
expression of endosialin warrant further consideration of endosialin as a therapeutic target to limit 
tumor progression and metastasis.  
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FIGURE LEGENDS 
Figure 1. Stromal endosialin promotes spontaneous metastasis, while not affecting primary 4T1 
tumor growth.  
A-E, 4T1 cells (2x105) were injected orthotopically into BALB/c WT and ENKO mice  A, Primary tumor 
growth (n=10-11 per group). B, Quantification of spontaneous lung metastases from 3 sections per 
mouse. Each data point represents one mouse. *,P<0.05. C, Representative H&E staining of lung 
sections. Arrowheads indicate metastatic lung lesions. Scale bar, 1mm. D, Kaplan-Meier survival 
curves after surgical removal of the primary tumor at day 9 or 10 (n=10-13 mice per group). E, 
Quantification of lung metastasis. *,P<0.05. F-I, 4T1-Luc cells (1x106) were orthotopically injected into 
Swiss nude WT (n=7) or ENKO (n=4) mice. F, Primary tumor growth (see Supplementary Fig. S2C for 
primary tumor growth of second experiment; WT, n=5; ENKO, n=4). G, Representative in vivo IVIS 
images at day 7. H, Quantification of spontaneous metastasis to organs monitored via ex vivo IVIS 
imaging 14 days after surgical primary tumor removal. Each data point represents one organ 
(combination of two independent experiments (WT, n=12; ENKO, n=8 mice)); see Supplementary Fig. 
S2D-I for individual organs; ***,P=0.0005; Mann-Whitney test. I, Representative ex vivo IVIS images. 
 
Figure 2.  Stromal endosialin promotes spontaneous metastasis of LLC tumors, while not affecting 
primary tumor growth.  
A, LLC cells (1x105) were subcutaneously injected into C57BL/6 WT and ENKO mice (n=10-11 mice per 
group) and allowed to grow for 16 days. B, Percentage of mice with metastases 19 days after surgical 
primary tumor removal (combination of two independent experiments (n=21 mice per group; 
*,P<0.05, Fischer´s exact test)). C, Representative images of resected lungs with corresponding H&E 
staining. Arrowheads indicate metastatic lung lesions. Scale bar, 1mm.  
 
Figure 3. Metastatic seeding or colonization is not affected by stromal endosialin.  
A-D, 4T1 cells (5x104) were injected intravenously into BALB/c WT and ENKO mice (n=9 per group). A, 
Quantification of tumor burden in lungs from IVIS images (day 14). Each data point represents one 
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mouse. B, Representative IVIS images. C, Quantification of lung metastatic area. Each data point 
represents one mouse. D, Representative H&E stained lung sections. Arrowheads indicate metastatic 
lesions. Scale bar, 1mm. E and F, LLC cells (1x106) were injected intravenously into C57BL/6 WT 
(n=11) and ENKO (n=6) mice. E, Quantification of lung colonization at day 14. Scoring: 0 = no tumor, 1 
= small metastatic foci, 2 = large metastatic foci covering 5 to 25% of section, 3 = large metastatic foci 
covering >25% of section. Each data point represents one mouse.  F, Representative images of 
resected lungs and corresponding H&E sections. Scale bar, 0.5mm. 
 
Figure 4. Vessel architecture and function in the primary tumor is no affected by stromal endosialin.  
A-C, 4T1 cells (2x105) were injected into BALB/c WT and ENKO mice (n=7 per group). A, Endomucin 
(red) and αSMA (green) stained tumor sections. Scale bar, 100μm. B, Quantification blood vessel 
density from 3 random fields per section. Each data point represents one mouse. C, Pericyte 
coverage quantified as % of blood vessels associated with αSMA+ pericytes from 3 random fields per 
section. Each data point represents one mouse. D-F, 4T1-Luc primary tumors in Swiss nude WT and 
ENKO mice (n=5-6 per group from Fig. 1F). D, CD31 (green) and desmin (red) stained tumor sections. 
Scale bar, 100µm. E, Quantification of CD31+ vessel area per total tumor area. F, Quantification of 
desmin+ area per total tumor area. G, Quantification of Hoechst dye in 4T1-tumor-bearing WT and 
ENKO BALB/c mice normalized to blood vessel density (n=4 per group). 3 random fields per tumor 
section were analyzed. H, Representative images. Scale bar, 100μm. I, 4T1 tumor bearing WT (n=11) 
or ENKO (n=8) BALB/c mice were injected with pimonidazole. Hypoxia was quantified as % of 
pimonidazole-positive tumor area per total tumor area. Each data point represents one mouse. J-L, 
4T1-Luc primary tumors in Swiss nude WT and ENKO mice (n=4-7 per group from Fig. 1F) were 
sectioned. J, Quantification of necrotic tumor area per total tumor area. K, Quantification of 
proliferation by Ki67+ cells per high power field of view. Data represents mean values from 5 random 
fields per tumor section. L, Representative images of Ki67 staining. Scale bar, 50µm. 
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Figure 5. Stromal endosialin promotes tumor cell dissemination. 
4T1-Luc-RFP cells (1x104) were injected orthotopically into BALB/c WT or ENKO mice (n=11 mice per 
group). A, Primary tumor growth. B, Quantification of lung metastasis by ddPCR. Data shown are the 
% RFP+ droplets relative to TFRC+. Each data point represents one mouse. *,P<0.05. C, Quantification 
of circulating tumor cells from 14 days cultured blood. Data are mean number of tumor colonies per 
100µL whole blood from 2 independent samples per animal *,P<0.05. Equivalent results were 
obtained in 2 independent experiments. D, Representative images of tumor cell colonies. 
 
Figure 6. Endosialin-expressing pericytes promote tumor cell intravasation in a cell contact-
dependent manner.  
See Supplementary Fig. S5 for experimental setup. A, shNT and shEN 10T1/2 cells stained for 
endosialin (green) or phalloidin (red). Scale bar, 75μm. B, Quantification of transmigrated 4T1-RFP 
cells through a Transwell layer of shNT and shEN 10T1/2 cells after 24 hours. Control wells contained 
no 10T1/2 cells. *,P<0.05, one-way ANOVA. C, Brain pericytes isolated from WT or ENKO BALB/c mice 
stained for endosialin (red) or endomucin (green). Scale bar, 75μm. D, Quantification of 
transmigrated 4T1-RFP cells through a Transwell layer of isolated WT and ENKO pericytes after 24 
hours. Data shown are combined from two independent experiments.  *,P<0.05, one-way ANOVA.  E, 
Quantification of transmigrated PKH67-labeled MDA-MB-231-LM2 cells through a Transwell layer of 
shNT or shEN human brain pericytes (BP) after 6 hours. Data shown are combined from 4 
independent experiments. *,P<0.05. F, Quantification of MDA-MB-231-LM2 transmigration as 
described in panel E except that HUVEC were first seeded on gelatin-coated Transwells overnight 
prior to the addition of BP. Control wells contained no pericytes. Data shown are combined from 5 
independent experiments. ***,P<0.001, **,P<0.01. G, Quantification of MDA-MB-231-LM2 
transmigration as described in panel F except that instead of BP, conditioned medium from shNT or 
shEN BP was added to the upper well 5 hours prior to addition of MDA-MB-231-LM2 cells. Data 
shown are combined from 3 independent experiments. H and I, Adhesion of 4T1-RFP tumor cells to a 
monolayer of (H) shNT or shEN 10T1/2 cells or (I) WT or ENKO mouse brain pericytes. Data show mean 
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of adherent cells from three wells per condition at each time point. ***,P<0.001. Equivalent results 
were obtained in an independent experiment. 
 
Figure 7. Endosialin expression in primary human breast cancer stroma primes for metastatic spread.  
A, Comparison of endosialin (CD248) expression in 6 matched cases of microdissected breast tumor 
stroma and normal adjacent stroma (34). ***,P=0.0003, Two-tailed paired t-test. B, Human breast 
cancer samples stained for endosialin using B1/35 (0.6mm invasive breast cancer cores) or FB5 
(whole invasive ductal carcinoma samples) antibody. Images illustrate negative, weak or strong 
endosialin expression in tumor stroma. Arrowheads indicate endosialin positive pericytes and 
myofibroblasts. Scale bar, 100µm. C, Quantification of stromal endosialin protein in invasive ductal 
carcinoma samples correlated to the lymph node metastasis status at the time of primary tumor 
removal and the distant metastasis status ~10 years after primary tumor removal. 47 patient samples 
analyzed. 8 patients, no metastasis; 19 patients, low metastatic potential (pN1a, 1-3 lymph nodes 
show tumors of 0.2cm size; 6 patients developed distant metastasis after primary tumor and lymph 
node removal); 12 patients, high metastatic potential (pN>1a, 4-10 lymph nodes show tumors of 
0.2cm size; 5 patients developed distant metastasis after primary tumor and lymph node removal); 
19 patients, distant metastasis (M1) to lung, brain, liver and bone. *,P<0.05, **,P<0.01. Two-tailed 
paired t-test. D, qPCR quantification (n=43) showing relative CD248 mRNA levels in primary tumor 
samples from patients with no metastasis (n=9), low metastatic potential (n=9, pN1a), high 
metastatic potential (n=8, pN>1a) and distant metastasis (n=17, M1). *, P<0.05. Two-tailed paired t-
test. E, Kaplan-Meier curves of recurrence-free survival assessed by the Finak et al. (34) dataset. 
P=0.0474, log-rank Mantel-Cox. F, Kaplan-Meier curves of distant metastasis-free survival assessed 
using publicly available data from Gyorffy et al. (35) (n=334 lymph node positive breast cancer 
samples). P=0.035, log-rank Mantel-Cox.  







